## ATTENTION ON ADHD: THE VALUE OF IMPROVING CARE FOR PEOPLE WITH ADHD SNAPSHOT



## **United Kingdom**

Overview of the ADHD Landscape in United Kingdom

COUNTRY C	CONTEXT	ගියියි DISEASE BURDEN	I/EPIDEMIOLOGY	P.	ADHD RESEARCH
Population 67,5	516,4961	ADHD prevalence rate for adults (1,025,	s (18-65) 2.5% <sup>5</sup> 602 patients) <sup>6</sup> **	Number of clinical trials (from 01.08.12 to 01.08.22)	)
Current health expenditure (% of GDP)	10.15% <sup>2</sup>	$\mathcal{P}$	REGISTRIES	۲ <u>: :</u>	NATIONAL GUIDELINES
Domestic general government health expenditure (% of GDP)		Is there a ADHD registry in the country?	NO INFO	NICE guidelines	YES
			RENCE CENTRES		
Out-of-pocket expenditure (%)	17.074	Number of reference centres / centres of excellence	NO INFO		

<sup>1</sup> World Population in Review. United Kingdom Population (estimate on 31 August) Available at: <u>https://worldpopulationreview.com/countries/united-kingdom-population</u> Last accessed October 2022.

- <sup>2</sup> The World Bank. Current Health expenditure (% of GDP) United Kingdom. Available at: https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=GB Last accessed October 2022.
- <sup>3</sup> The World Bank. Domestic general government health expenditure (% of GDP) United Kingdom. Available at: https://data.worldbank.org/indicator/SH.XPD.GHED.GD.ZS?locations=GB Last accessed October 2022.
- <sup>4</sup> The World Bank. Out-of-pocket expenditure (% of current health expenditure) United Kingdom. Available at: <u>https://data.worldbank.org/indicator/SH.XPD.OOPC.CH.ZS?locations=GB</u> Last accessed October 2022.
- <sup>5</sup> Faraone S V., Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021 Sep 1;128:789–818.
- <sup>6</sup> Population data ONS Mid-2020 Population Estimates for 2021 Clinical Commissioning Groups in England by Single Year of Age and Sex, Persons National Statistics Last Accessed 23/02/2022
- <sup>7</sup> EU Clinical Trials Register. Last accessed November 2022. Available at: <u>https://www.clinicaltrialsregister.eu/</u>

\*Treating to 70% of the estimated prevalence of patients means increasing rates of diagnosis meaning that the percentage of patients increases by 30% from 40-70 leading to a higher number of patients being treated in the health system). \*\*Adult patient population is calculated by multiplying the ADHD prevalence rate from Faraone et al, 2021 by the country's 18-65 population data (see endnotes).

The Attention on ADHD site has been initiated and funded by Takeda. Copyright 2023 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.

Job number: C-ANPROM/EUC/ADH/0030